Tonix Pharmaceuticals

3:45 PM - 4:00 PM (PDT), Monday, June 13, 2022
Tonix Pharmaceuticals is committed to improving the lives of patients by identifying, researching and developing promising therapies which have the potential to address unmet needs. We are developing both small molecule drugs and biologics across a range of therapeutic areas, focusing on prevention and treatment of infectious diseases, central nervous system disorders and immunology conditions.
Ticker:
TNXP
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
TNX-1500 (anti-CD40L mAb)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
Chief Executive Officer
TONIX Pharmaceuticals, Inc